BSX 10-K Annual Reports

Boston Scientific Corporation (BSX) reported a strong financial performance for the year ended December 31, 2025, with reported net sales increasing by 19.9% to $20.074 billion and reported net income attributable to common stockholders growing by 56.4% to $2.898 billion. This growth was primarily driven by robust commercial execution across its key business segments, particularly the Electrophysiology unit, fueled by the continued success of the FARAPULSE™ Pulsed Field Ablation System. The company also saw significant contributions from its Cardiovascular and Urology segments. Looking ahead, Boston Scientific announced its definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion, a strategic move expected to enhance its presence in the thrombectomy market. The company also completed several key acquisitions during the year, including Bolt Medical, SoniVie Ltd., and Intera Oncology, Inc., further strengthening its product portfolio and market position. With a solid cash position and access to credit facilities, the company believes it has sufficient liquidity to fund its operations, strategic initiatives, and upcoming acquisitions.

Boston Scientific Corporation (BSX) reported strong financial performance for the fiscal year ended December 31, 2024. Net sales increased significantly by 17.6% to $16.747 billion, driven by robust commercial execution across all business units, particularly the Electrophysiology segment benefiting from the successful launch and rapid adoption of the Farapulse™ Pulsed Field Ablation System. The company also completed strategic acquisitions, including Axonics, Inc. and Silk Road Medical, Inc., which are expected to contribute to future growth. Profitability saw a substantial increase, with reported net income attributable to common stockholders reaching $1.853 billion ($1.25 per diluted share). On an adjusted basis, which excludes certain charges and credits, net income was $3.725 billion ($2.51 per diluted share). The company maintained a strong balance sheet and positive cash flow from operations, indicating effective management of resources and strategic investments. BSX continues to focus on innovation and expanding its global presence, positioning itself for continued growth in the medical technology sector.

Boston Scientific Corporation (BSX) has filed its 2023 Annual Report (10-K/A) on February 20, 2024, reflecting their performance for the period ending December 30, 2023. While the provided excerpt focuses on exhibit information, a full 10-K filing would detail the company's financial performance, strategic initiatives, risk factors, and management's discussion and analysis. Investors should review the complete filing to understand BSX's revenue growth, profitability trends, debt levels, and any significant changes in its product portfolio or market position. Key areas for investor attention in the full report typically include the company's performance across its various segments (e.g., Cardiovascular, MedSurg, Pelvic Health, Neuromodulation), any notable acquisitions or divestitures, ongoing research and development efforts, and the competitive landscape. The filing also contains crucial information on the company's outlook and forward-looking statements, which are essential for assessing future growth prospects and potential risks.

Boston Scientific Corporation (BSX) reported a strong fiscal year 2023 with net sales reaching $14.24 billion, a 12.3% increase compared to 2022. This growth was driven by robust organic net sales growth of 12.3% and strategic acquisitions, demonstrating the company's diversified product portfolio and effective commercial execution across its MedSurg and Cardiovascular segments. Financially, the company reported a net income of $1.57 billion ($1.07 per diluted share) for 2023. On an adjusted basis, excluding certain charges and credits, adjusted net income was $3.00 billion ($2.05 per diluted share), highlighting operational improvements and strategic reinvestments. The company also strengthened its balance sheet, with significant operating cash flow and a healthy leverage ratio, positioning it well for future growth and strategic initiatives, including the pending acquisition of Axonics, Inc.

Boston Scientific Corporation (BSX) reported strong net sales growth of 6.7% to $12.68 billion for the fiscal year ended December 31, 2022. This growth was driven by a combination of operational expansion, strategic acquisitions, and a diverse product portfolio, particularly in the Cardiovascular and MedSurg segments. Despite facing headwinds from foreign currency fluctuations and global supply chain challenges, the company demonstrated resilience. Financially, BSX reported a net income of $642 million, or $0.45 per diluted share. On an adjusted basis, excluding certain charges and credits, net income was $2.46 billion, or $1.71 per diluted share. The company maintained a robust balance sheet with $928 million in unrestricted cash and cash equivalents and a strong credit facility. The company's strategic imperatives focus on strengthening category leadership, expanding into high-growth adjacencies, and driving global expansion, which are supported by ongoing investments in research and development.

Boston Scientific Corporation (BSX) reported a significant increase in net sales for the year ended December 31, 2021, reaching $11.888 billion, a 19.9% increase compared to 2020. This growth was primarily driven by the recovery of elective and semi-emergent medical procedures, which were impacted by the COVID-19 pandemic in the prior year. The company's strategic acquisitions, including Preventice Solutions, Farapulse, and Lumenis's global surgical business, also contributed positively to the sales performance. While the company reported a net income of $985 million ($0.69 per diluted share), adjusted net income, excluding certain charges and credits, was $2.336 billion ($1.63 per diluted share), reflecting strong operational performance. The company's gross profit margin improved to 68.8% in 2021, up from 65.0% in 2020, attributed to higher sales volumes and a favorable product mix, though offset by inflationary pressures on raw materials and freight. Looking ahead, Boston Scientific is focused on its strategic imperatives, including strengthening category leadership and expanding into high-growth adjacencies. The company maintains a strong liquidity position with $1.925 billion in unrestricted cash and cash equivalents. However, ongoing challenges include managing supply chain disruptions, potential increases in costs, and navigating a dynamic regulatory and reimbursement landscape. The company also reported substantial litigation-related charges, particularly concerning transvaginal surgical mesh products. Despite these challenges, BSX demonstrated resilience and a clear growth trajectory in 2021, driven by its diverse product portfolio and strategic initiatives.

Boston Scientific Corporation's (BSX) 2020 Form 10-K filing reveals a challenging year impacted by the COVID-19 pandemic, which led to a 7.7% decrease in net sales, reaching $9.91 billion. The company reported a net loss of $82 million for the year. Despite the revenue decline, BSX demonstrated resilience through strategic cost management and a focus on its core product franchises across MedSurg, Rhythm and Neuro, and Cardiovascular segments. The company continues to invest in research and development to drive innovation and maintain its competitive edge in the medical device market. Key strategic imperatives include strengthening category leadership and expanding into high-growth adjacencies. BSX also made progress in its sustainability initiatives and diversity, equity, and inclusion efforts, underscoring its commitment to corporate social responsibility. The divestiture of its Specialty Pharmaceuticals business is planned for the first half of 2021, aiming to streamline operations and focus on its core medical device portfolio.

Boston Scientific Corporation's 2019 10-K filing highlights a year of robust growth, driven significantly by strategic acquisitions, most notably BTG plc. The company reported net sales of $10.735 billion, an increase of 9.3% over the prior year, with operational growth of 11.1%. This growth was broadly distributed across its key segments, including Cardiovascular and MedSurg, with notable contributions from product launches and advancements in structural heart therapies and peripheral interventions. The company's financial performance was impacted by various charges and credits, including acquisition-related costs and a significant deferred tax benefit related to intellectual property transfers, resulting in a reported net income of $4.700 billion. Management, however, emphasizes adjusted net income of $2.234 billion for a clearer view of underlying operational performance. Boston Scientific's strategic imperatives focus on strengthening category leadership, expanding into high-growth adjacencies, and driving global expansion, supported by continued investment in research and development. The company maintains a strong balance sheet and adequate liquidity, though it navigates an evolving healthcare landscape with pricing pressures and regulatory changes, particularly the upcoming EU MDR implementation.

Boston Scientific Corporation (BSX) reported strong net sales growth of 8.6% for fiscal year 2018, reaching $9.823 billion. This growth was driven by an 8.0% operational increase, supplemented by favorable foreign currency fluctuations. The company's strategy focuses on strengthening category leadership, expanding into high-growth adjacencies, driving global expansion, and developing key capabilities. Key product areas contributing to this performance include Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, and Urology and Pelvic Health, with notable growth in structural heart therapies and neuromodulation. The company completed several strategic acquisitions in 2018, including Augmenix, Claret Medical, and NxThera, to enhance its product portfolio and market position. Financially, Boston Scientific reported a significant increase in net income to $1.671 billion ($1.19 per diluted share) in 2018, compared to $104 million ($0.08 per diluted share) in 2017. This improvement was supported by operational growth and a reduction in certain charges, though the company also noted significant investments in research and development and ongoing restructuring initiatives. Looking ahead, the company is pursuing the acquisition of BTG plc, expected to close in the first half of 2019, which is anticipated to further bolster its offerings in minimally invasive procedures for cancer and vascular diseases.

Boston Scientific Corporation (BSX) reported significant progress in its 2017 fiscal year, demonstrating robust revenue growth driven by strong performance across its diverse product portfolio. The company's strategic imperatives, including strengthening category leadership and expanding into high-growth adjacencies, appear to be yielding positive results, as evidenced by increases in net sales across multiple business segments like Interventional Cardiology, Peripheral Interventions, and MedSurg. Acquisitions, such as Symetis SA and EndoChoice Holdings, Inc., also contributed to this growth, with ongoing integration efforts expected to further enhance market position. Financially, BSX navigated a complex market, managing expenses effectively while continuing to invest in research and development. While the company reported a net income of $104 million ($0.08 per diluted share) on a GAAP basis, adjusted net income (excluding certain charges and credits) was significantly higher at $1.752 billion ($1.26 per diluted share), highlighting the impact of significant non-recurring items, including litigation-related charges and the Tax Cuts and Jobs Act. The company maintained investment-grade credit ratings and demonstrated strong cash flow from operations, supporting its liquidity and capital resource needs. Investors should note the substantial ongoing litigation reserves and the company's strategic focus on innovation and market expansion.

Boston Scientific Corporation (BSX) filed its 2016 annual report on Form 10-K, presenting a comprehensive overview of its financial performance and strategic positioning. The report highlights the company's continued focus on innovation and growth across its diverse medical device segments. Investors should note the company's revenue drivers and its ongoing efforts to manage costs and optimize its product portfolio. Key areas of attention include the performance of its cardiovascular, rhythm management, and endoscopy divisions, as well as its strategic acquisitions and divestitures aimed at enhancing market share and profitability. The company's financial results for 2016 demonstrate a commitment to operational efficiency and strategic execution. BSX has been actively investing in research and development to bring new products to market and expand its global reach. While navigating a competitive healthcare landscape, Boston Scientific appears to be making strides in key therapeutic areas, positioning itself for sustained growth. Investors will want to closely examine the company's balance sheet, cash flow generation, and its outlook for the coming fiscal year.

Boston Scientific Corporation (BSX) reported significant net sales growth of 12% in 2016, reaching $8.386 billion. This growth was driven by strong performance across its key business segments, notably Urology and Pelvic Health (45% increase, bolstered by acquisitions) and Interventional Cardiology (12% increase, driven by drug-eluting stents and structural heart products). The company's strategic focus on innovation and market expansion appears to be yielding positive financial results, with adjusted net income showing a substantial increase. However, the report also highlights significant litigation-related charges, particularly from transvaginal surgical mesh cases, which impacted reported net income. The company continues to invest heavily in research and development, underscoring its commitment to future growth through new product introductions and technological advancements. Despite facing competitive pressures and regulatory complexities inherent in the medical device industry, Boston Scientific demonstrated solid operational execution and revenue generation in 2016.

Boston Scientific Corporation (BSX) reported fiscal year 2015 net sales of $7.477 billion, a slight increase of 1% year-over-year. However, excluding the significant negative impact of foreign currency fluctuations ($505 million), net sales grew by a more robust 8%. This growth was driven by strong performance in its Peripheral Interventions, Urology and Pelvic Health (bolstered by the August 2015 acquisition of the American Medical Systems male urology portfolio), and Neuromodulation businesses. The company reported a net loss of $239 million ($0.18 per share) for the year. This loss was substantially impacted by significant non-GAAP adjustments, including substantial litigation-related charges ($1.105 billion), acquisition- and divestiture-related charges, and restructuring costs. Excluding these items, adjusted net income was $1.267 billion ($0.93 per share). The company continues to invest in its strategic imperatives, focusing on strengthening execution, expanding into high-growth adjacencies through strategic acquisitions, driving global expansion, managing costs, and developing key capabilities. The acquisition of the AMS male urology portfolio for $1.616 billion was a key strategic move in 2015, expanding its Urology and Pelvic Health segment. Boston Scientific also made progress in its key product launches and pipeline development, including the WATCHMAN device in the U.S. and its Lotus Valve System in Europe. Financially, the company's debt levels increased to $5.677 billion primarily due to funding acquisitions. While operating cash flow decreased significantly in 2015 due to litigation-related payments, the company maintained its investment-grade credit ratings. Investors should monitor the resolution of ongoing litigation and the company's ability to integrate its recent acquisitions effectively while managing its debt.

Boston Scientific Corporation's (BSX) 2014 10-K filing highlights a year of revenue growth and strategic acquisitions, alongside significant litigation charges. Net sales increased by 3% to $7.38 billion, driven by strong performance in Interventional Cardiology, Electrophysiology, Endoscopy, and Peripheral Interventions. However, the company reported a net loss of $119 million, largely impacted by a $600 million settlement with Johnson & Johnson related to the Guidant acquisition. Excluding these and other charges, adjusted net income was $1.13 billion, or $0.84 per share. The company continued to execute its five strategic imperatives: strengthening execution to grow share, expanding into high-growth adjacencies, driving global expansion, funding growth initiatives, and developing key capabilities. Key acquisitions during the year included the Interventional Division of Bayer AG and IoGyn, Inc., aimed at strengthening the company's product portfolio and market position. BSX emphasizes its commitment to innovation, investing $817 million in R&D. The company also returned value to shareholders through $125 million in share repurchases. Despite ongoing healthcare policy changes and pricing pressures, Boston Scientific maintains an optimistic outlook, focusing on its diverse product portfolio and strategic growth opportunities.

Boston Scientific Corporation's 2013 10-K filing reveals a year of strategic recalibration, with net sales slightly decreasing year-over-year to $7.143 billion. This dip was influenced by foreign currency fluctuations and the ongoing impact of divested businesses. However, on a constant currency and adjusted basis, the company saw underlying growth driven by its Endoscopy, Neuromodulation, and Peripheral Interventions segments. The company reported a net loss of $121 million for the year, largely due to significant goodwill and intangible asset impairment charges, restructuring costs, and litigation expenses. Despite these headwinds, Boston Scientific demonstrated a commitment to innovation with new product launches and continued investment in research and development, including advancements in coronary stent systems like the Promus PREMIER™ and the SYNERGY™ system. The company also made strides in its structural heart therapy and cardiac rhythm management segments, highlighting a focus on expanding its less-invasive medical device portfolio.

Boston Scientific Corporation's (BSX) 2012 annual report (filed February 2013) highlights a company navigating both challenges and opportunities in the medical device sector. While specific financial performance details beyond the filing date are not provided in this excerpt, the report's emphasis on its business segments suggests a strategic focus on key growth areas. Investors should note the company's ongoing commitment to innovation and market expansion as drivers for future performance. The inclusion of the Consent of Independent Registered Public Accounting Firm, Ernst & Young LLP, indicates that the financial statements have undergone external audit, a standard practice for investor confidence.

Boston Scientific Corporation's 2012 10-K filing reveals a year of significant restructuring and a focus on key growth areas, despite a net loss driven by substantial goodwill and intangible asset impairment charges totaling $4.492 billion. The company generated $7.249 billion in net sales, a 5% decrease from 2011, primarily due to declines in the Interventional Cardiology and Cardiac Rhythm Management (CRM) segments. However, the Endoscopy and Peripheral Interventions businesses showed growth. Strategic acquisitions in 2012, including Cameron Health (S-ICD system), BridgePoint Medical, Rhythmia Medical, and Vessix Vascular, demonstrate a commitment to expanding the product portfolio in high-growth adjacencies. The company also reported progress on its restructuring initiatives aimed at improving operational efficiency and cost structure. Despite the reported net loss, adjusted net income was $933 million. Key financial metrics like operating cash flow ($1.260 billion) and maintaining investment-grade credit ratings highlight underlying operational strengths. The company's strategy emphasizes strengthening execution, expanding into high-growth areas, driving global expansion, and managing costs effectively.

Boston Scientific Corporation's (BSX) 2011 Form 10-K highlights a year of strategic repositioning and operational adjustments. The company reported net sales of $7.62 billion, a slight decrease from the prior year, impacted by the divestiture of its Neurovascular business. Despite the sales decline, adjusted net income remained robust, reflecting successful cost-containment measures and restructuring initiatives aimed at improving operational efficiency and profitability. The company continued to invest in research and development, focusing on innovation across its key business segments, including Interventional Cardiology, Cardiac Rhythm Management (CRM), Endoscopy, and Peripheral Interventions. Key financial and operational themes for 2011 include managing pricing pressures in core markets like coronary stents and CRM, investing in emerging markets, and navigating a complex regulatory and reimbursement environment. The company made significant strides in debt reduction, improving its credit ratings, and repurchased a substantial amount of its common stock. Despite facing challenges such as competition and evolving healthcare policies, Boston Scientific emphasized its commitment to innovation and delivering value to patients and shareholders through its diversified portfolio of less-invasive medical devices.

Boston Scientific Corporation (BSX) filed its 2010 Form 10-K on February 16, 2011, indicating its status as a large accelerated filer. The company reported an aggregate market value of common stock held by non-affiliates of approximately $8.6 billion as of June 30, 2010, with 1,523,368,979 shares outstanding as of January 31, 2011. This filing provides a comprehensive overview of the company's business, risk factors, financial condition, and results of operations for the fiscal year ended December 30, 2010. Investors should pay close attention to the Management's Discussion and Analysis (MD&A) for insights into the company's performance drivers, strategic initiatives, and future outlook. While detailed financial statements and operational data are not included in the provided excerpt, the structure of the 10-K indicates that investors can find critical information regarding BSX's market position, financial health, and potential challenges. The inclusion of "Risk Factors" and "Legal Proceedings" sections suggests that investors should be aware of potential headwinds and litigation risks that could impact the company's performance and valuation. The reference to incorporated documents, such as the proxy statement, also suggests that further information on corporate governance and executive compensation will be available.

Boston Scientific Corporation's 2009 10-K filing paints a picture of a company navigating a challenging economic environment while making strategic moves. The report highlights efforts to manage costs and streamline operations, crucial for maintaining profitability in a competitive medical device market. Investors should note the company's focus on innovation and product development, which are key drivers for future growth. While specific financial figures from the provided table of contents are limited, the structure of the report suggests a comprehensive review of the company's performance, risks, and strategic direction. The filing also underscores the importance of regulatory compliance and legal proceedings, which can significantly impact financial performance and investor confidence. The inclusion of various agreements and stipulations, such as a Plea Agreement and Corporate Integrity Agreement, indicates a proactive approach to addressing past issues. Investors will want to pay close attention to the Management's Discussion and Analysis (MD&A) and the Financial Statements for a deeper understanding of the company's financial health and operational strategies.

Boston Scientific Corporation's (BSX) 2008 10-K filing reveals a challenging year marked by a significant net loss primarily driven by substantial goodwill and intangible asset impairment charges totaling $2.79 billion. This impairment was largely attributed to the impact of disruptions in the credit and equity markets following the 2006 Guidant acquisition. Despite the net loss, the company generated robust operating cash flow of $1.216 billion, demonstrating operational resilience. Net sales saw a slight decrease of 4% to $8.05 billion, impacted by increased competition in the drug-eluting stent market and the divestiture of non-strategic businesses. However, growth was observed in the Cardiac Rhythm Management (CRM) segment, up 8%, and Endosurgery, up 8%, highlighting strategic product launches and market penetration. The company is actively managing its financial position by reducing debt, having prepaid $1.425 billion under its term loan and credit facility in 2008. Furthermore, Boston Scientific is implementing cost-saving measures, including a plant network optimization plan aimed at simplifying manufacturing and improving gross margins. The company's product portfolio remains strong, with continued investment in innovation for both CRM and cardiovascular devices. Key risks highlighted include intense competition, regulatory scrutiny, and the ongoing impact of economic downturns on healthcare spending and reimbursement.

Boston Scientific Corporation's (BSX) 2007 10-K filing reveals a year of significant strategic restructuring, marked by sales of non-core businesses and a focus on optimizing operations. Despite a reported net loss of $495 million, the company's net sales grew 7% to $8.36 billion, largely driven by the acquisition of Guidant Corporation, which bolstered its Cardiac Rhythm Management (CRM) segment. However, sales in the crucial coronary stent business saw a notable decline of 19%, primarily due to market concerns surrounding late stent thrombosis and decreased procedural volumes. The company is actively managing its debt, which stood at $8.19 billion at year-end 2007, and is implementing cost-reduction initiatives aimed at improving financial performance and focusing on core growth areas. The company's strategic initiatives included divesting five non-strategic businesses, leading to approximately 2,000 job reductions. These actions are intended to streamline operations and improve financial flexibility. Despite the reported net loss, the company's operational cash flow remained positive at $934 million, and it continues to invest in research and development, albeit with a strategic realignment to focus on key product lines like drug-eluting stents and CRM technologies. Management is focused on navigating the challenges in the drug-eluting stent market and rebuilding confidence in its CRM offerings while working to resolve outstanding FDA matters.

Boston Scientific Corporation (BSX) reported its 2006 annual results, a year marked by the transformative acquisition of Guidant Corporation. This acquisition significantly expanded BSX's footprint, particularly in the Cardiac Rhythm Management (CRM) and Cardiac Surgery sectors, establishing it as a major player in cardiovascular devices. While the Guidant acquisition drove a substantial increase in net sales to $7.821 billion, the company reported a net loss of $3.577 billion for the year, primarily due to significant one-time acquisition-related charges, including purchase accounting adjustments and integration costs. The company faced challenges in its core coronary stent business, with sales declining due to market concerns over late stent thrombosis, although regulatory panels continued to affirm the safety and efficacy of drug-eluting stents. Despite the reported net loss, the company generated strong operating cash flow and maintained a focus on innovation and quality improvement. The integration of Guidant presented both opportunities and challenges, with ongoing restructuring efforts planned to optimize operations. BSX also addressed regulatory issues, including FDA warning letters at several facilities, and made progress on remediation efforts. Looking ahead, the company aimed to leverage its expanded product portfolio, particularly in the CRM and drug-eluting stent markets, while managing its debt obligations incurred from the Guidant acquisition.

Boston Scientific Corporation's 2005 10-K filing highlights a year of significant strategic activity, particularly the substantial acquisition of Guidant Corporation. This acquisition, valued at approximately $27 billion, is positioned as a transformative event expected to create a global leader in cardiovascular devices and expand Boston Scientific's product portfolio and market reach significantly. The company emphasizes the integration of Guidant's operations as a primary focus for the upcoming year, anticipating synergies and enhanced competitive positioning. While the acquisition dominated strategic discussions, the report also touches upon ongoing product development and market challenges across its diversified medical device segments. Investors should note the significant financial commitments and potential integration risks associated with the Guidant deal, alongside the company's stated confidence in its ability to realize growth and operational efficiencies. The filing underscores a commitment to innovation and market leadership, albeit with the inherent complexities of such a large-scale integration.

Boston Scientific Corporation's 2004 10-K report highlights a year of significant growth, driven primarily by the strong performance of its TAXUS® Express 2™ paclitaxel-eluting coronary stent system. Net sales surged by 62% to $5.62 billion, with the TAXUS stent system alone accounting for 38% of total net sales, underscoring its critical role in the company's revenue. The company is strategically positioned to capitalize on the expanding drug-eluting stent market, which it anticipates will constitute the majority of the coronary stent market in the coming years. Boston Scientific is also actively investing in its research and development pipeline, pursuing next-generation technologies and expanding into new therapeutic areas such as neuromodulation through its acquisition of Advanced Bionics Corporation. While the company faces ongoing patent litigation and competitive pressures, its focus on innovation, product diversity, and operational excellence aims to sustain its market leadership.

Boston Scientific Corporation's 2003 10-K report highlights a company firmly established in the medical device market, focused on less-invasive medicine. A significant strategic emphasis is placed on the burgeoning drug-eluting stent (DES) market, particularly with the upcoming U.S. launch of the TAXUS™ paclitaxel-eluting coronary stent system, expected to drive substantial revenue growth. The company leverages a broad product portfolio across interventional cardiology and endosurgery, supported by a robust business strategy centered on innovation, clinical excellence, product diversity, operational efficiency, and focused marketing. Despite a competitive landscape and ongoing patent litigation, Boston Scientific is positioning itself for continued leadership and expansion, particularly in high-growth areas like cardiovascular interventions.

Boston Scientific Corporation's 2002 Form 10-K report highlights its position as a leading developer, manufacturer, and marketer of less-invasive medical devices. The company operates across various interventional specialties, with a significant focus on its Cardiovascular and Endosurgery business segments, which contributed approximately 68% and 32% of net sales, respectively, in 2002. A key strategic focus is the development and commercialization of drug-eluting coronary stents, particularly the TAXUS system, which represents a significant growth opportunity in a dynamic and competitive market. The company is actively pursuing regulatory approvals, with expedited review status granted by the FDA for the TAXUS system, anticipating a U.S. launch in late 2003. Boston Scientific continues to drive growth through innovation, product diversity, clinical excellence, and operational efficiency. The company has also actively pursued strategic acquisitions and alliances to expand its product portfolio and technological capabilities, as demonstrated by recent acquisitions in women's health and neurovascular, and alliances in pain management and brain monitoring. The company emphasizes its commitment to quality, driven by comprehensive quality systems certified under various international standards. Despite competitive pressures and evolving healthcare reimbursement landscapes, Boston Scientific is positioned to leverage its broad product line and focused marketing strategies to maintain and grow its market share.

Boston Scientific Corporation's 2001 Form 10-K highlights a year of significant strategic growth, marked by key product developments and a robust acquisition strategy. The company, a leader in less-invasive medical devices, focused on expanding its portfolio across interventional cardiology, electrophysiology, gastroenterology, and other specialties. Significant progress was made with the launch of the Express™ coronary stent in international markets and advancements in the TAXUS™ drug-eluting stent program, which showed promising zero-restenosis and zero-thrombosis results in early trials. Financially, the company's growth has been fueled by both internal development and a series of strategic acquisitions in 2001, including those in electrophysiology, venous access, embolic protection, and oncology. These moves aim to solidify Boston Scientific's position as a comprehensive provider of less-invasive medical solutions. The report also details ongoing efforts in clinical trials to support new product approvals and market expansion, particularly for the TAXUS stent in the U.S. Investors should note the company's strong emphasis on innovation, clinical excellence, and operational efficiency as drivers for future success, alongside potential pressures from cost containment in healthcare and competitive pricing.

Boston Scientific Corporation's 2000 10-K report highlights a company deeply invested in the development, manufacturing, and marketing of less invasive medical devices. The company's strategy centers on product diversity, continuous innovation, operational excellence, focused marketing, and an expanding international presence. In 2000, international sales constituted a significant 41% of total net sales, underscoring the global reach of its operations. The company's product portfolio spans a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, and neuro-endovascular therapy. Growth has been historically driven by strategic acquisitions and alliances, and the company has several strategic initiatives and acquisitions planned or completed in early 2001, indicating an ongoing commitment to expanding its market share and technological capabilities. The report also details significant investments in research and development, with approximately $199 million spent in 2000, representing about 7% of net sales, to fuel future innovation.

This filing represents an amendment to Boston Scientific Corporation's (BSX) 1998 Annual Report (10-K). As an amendment, it likely contains corrections or additions to previously filed information, but the provided text is primarily navigational and descriptive of the SEC's EDGAR system rather than containing specific financial data. Investors should consult the original 10-K filing and any subsequent amendments for detailed financial performance, risk factors, and management's discussion and analysis. The focus of this document is on the filing's metadata and its location within the SEC's archival system.

This 10-K Annual Report Amendment filing from Boston Scientific Corp (BSX) on April 28, 1999, pertains to the fiscal period ending December 30, 1998. As this is an amendment, it suggests that the company is providing updated or corrected information to its initial filing. Investors should note that this filing is from 1999, and therefore, reflects the company's financial and operational status over two decades ago. While historical, it provides a snapshot of the company's position at that time, which could be relevant for understanding its long-term trajectory and evolution. Key details regarding the company's performance, financial health, and any significant events or risk factors during the 1998 fiscal year would be within the detailed sections of the full 10-K. Investors interested in the company's historical performance should review these sections to understand its growth, product portfolio, and market position at the turn of the millennium. This amendment highlights the importance of reviewing filings carefully for any changes or clarifications provided by the company.

This filing is an amendment to Boston Scientific Corp.'s (BSX) 1997 Annual Report (10-K), filed on March 31, 1999. As an amendment, it suggests that the original filing may have contained errors or omissions that are now being corrected. Investors should focus on understanding the nature of the amendments, as they could impact the company's previously reported financial performance, operational status, or risk disclosures for the fiscal year ending December 30, 1997. The filing details are provided through a directory listing of the archived EDGAR data, indicating the availability of the amended document and related files for review. Given the age of the filing, the information pertains to a historical period and should be viewed in the context of BSX's evolution since 1997. Investors interested in this period should consult the actual amended filing document for specific details.

Boston Scientific Corporation's (BSX) 1998 10-K filing provides a snapshot of its operations and financial standing as of December 30, 1998. The company is engaged in the development, manufacturing, and marketing of medical devices. While specific financial performance metrics are not detailed in the provided excerpt, the filing indicates the company's focus on innovation and market presence within the medical technology sector. Investors should note the period covered and the filing date, which predate significant market shifts and company developments. This report serves as a foundational document for understanding BSX's position at the close of 1998. Further analysis would require accessing the full financial statements, management's discussion and analysis (MD&A), and details on product lines, market strategies, and competitive landscape to assess its growth trajectory and investment potential at that time.

This 10-K filing for Boston Scientific Corp. (BSX) for the period ending December 30, 1997, filed on March 31, 1998, represents a snapshot of the company's financial health and strategic positioning at a crucial time in its growth. As an investor, understanding the context of this filing is vital, as it precedes significant developments and showcases the company's foundational strengths and potential for future expansion within the medical device industry. The filing details the company's operations, financial performance, and risk factors, providing a basis for evaluating its investment merit. Investors should pay close attention to the detailed financial statements and management's discussion and analysis to understand the company's revenue streams, profitability, and any identified challenges. This report serves as a critical document for assessing the company's trajectory and its ability to navigate the competitive landscape of medical technology.

This 10-K filing from Boston Scientific Corp (BSX) for the period ending December 30, 1996, and filed on March 31, 1997, represents a snapshot of the company's financial and operational standing at a critical juncture in its history. As a medical device company, BSX was likely focused on growth through innovation and market expansion during this era. Investors would be interested in the company's revenue streams, profitability, product pipeline, and any significant strategic developments, such as acquisitions or new product launches that would have shaped its competitive position.